Editorial Board

Editor-in-chief

Paige Samson, FDLI

Assistant Editor

Jennifer Nessel, FDLI

FDLJ Editorial Advisory Board

Paige Samson (Staff Liaison), FDLI
Nathan A. Beaton, Latham & Watkins LLP
Laurie J. Beyranevand, Vermont Law School
Brigid Bondoc, Morrison and Foerster, LLP
Marie Boyd, University of South Carolina
Nathan A. Brown, Akin Gump Strauss Hauer & Feld LLP
Christine P. Bump, Penn Avenue Law & Policy
Jonathan M. Cohen, K&L Gates LLP
Michelle Divelbiss, Covington & Burling LLP
Bridget C.E. Dooling, George Washington University
Jamie W. Gamerman, FDA – CDER
Lewis A. Grossman, American University
Emily C. Helms Williams, FDA – OC
Peter Barton Hutt, Covington & Burling LLP
William M. Janssen, Charleston School of Law
John F. Johnson III, Shook, Hardy & Bacon LLP
Alan C. Katz, toXcel, LLC
Geoffrey M. Levitt, DLA Piper LLP (US)
Peter V. Lindsay, Paul Hastings, LLP
Markham C. Luke, FDA – CDER
Catherine A. Melfi, Omeros Corporation
Cynthia L. Meyer, Kleinfeld, Kaplan & Becker, LLP
Alan G. Minsk (Chair), Arnall Golden Gregory LLP
Adam Muchmore, Penn State Law
James O’Reilly, University of Cincinnati
Daniel Orr, Thomson Reuters
Somnath Pal, St. John’s University College of Pharmacy
Tyler Scandalios, Arnold & Porter LLP
Shy Shorer, National Institutes of Health
David Simon, Harvard Law School
Anna Sims, FDA – OC
Eric Solowey, Parexel International Corporation
Andrew Wasson, Haug Partners LLP
Emily Wright, Pfizer Inc.